SELECXINE
- Employees
- 1–10
- Business Model
- B2B
- Website
- selecxine.com
- Total Funding
- $12.0M
- Last Round
- $12.0M Series BJan 2022
- Rounds
- 2
About
Biopharmaceutical startup developing immunotherapeutics and immune-mediated anti-cancer drugs using cytokine and related mechanisms.
Summary
SELECXINE is a Biotech company. It has raised $12.0M in total across 2 rounds, most recently a $12.0M Series B round in Jan 2022. Investors include Stonebridge Capital, STIC Ventures and Hanwha Investment & Securities.
Sign up to view the funding chart
Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.
Funding History
Jan 2022
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company